{"_id": "W2100000001", "title": "Mechanisms of PD-1/PD-L1 checkpoint blockade in cancer immunotherapy", "text": "Programmed death-1 (PD-1) and its ligand PD-L1 constitute a major immune checkpoint pathway that tumors exploit to evade immune surveillance. This review discusses the molecular mechanisms underlying PD-1/PD-L1 interactions and their role in T cell exhaustion. We examine how therapeutic antibodies targeting this axis restore anti-tumor immunity and discuss resistance mechanisms that limit clinical efficacy. Understanding these pathways is crucial for developing combination strategies.", "metadata": {"doi": "10.1038/nri.2018.1", "journal": "Nature Reviews Immunology", "publication_date": "2018-03-15", "mesh_terms": ["PD-1", "PD-L1", "Immunotherapy", "T-Lymphocytes"]}}
{"_id": "W2100000002", "title": "CTLA-4 blockade and the emergence of cancer immunotherapy", "text": "Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) was the first immune checkpoint receptor to be targeted in cancer therapy. This article reviews the discovery of CTLA-4 as a negative regulator of T cell activation and the development of ipilimumab, the first checkpoint inhibitor approved for cancer treatment. We discuss the mechanism of action, clinical trial results, and immune-related adverse events associated with CTLA-4 blockade.", "metadata": {"doi": "10.1126/science.aat4236", "journal": "Science", "publication_date": "2017-06-22", "mesh_terms": ["CTLA-4", "Ipilimumab", "Melanoma", "T-Cell Activation"]}}
{"_id": "W2100000003", "title": "CAR-T cell therapy: engineering T cells for cancer treatment", "text": "Chimeric antigen receptor (CAR) T cell therapy represents a paradigm shift in cancer treatment. By genetically modifying patient T cells to express synthetic receptors targeting tumor antigens, CAR-T therapy has achieved remarkable responses in hematological malignancies. This review covers CAR design principles, manufacturing processes, clinical outcomes in B-cell malignancies, and emerging strategies to extend CAR-T therapy to solid tumors.", "metadata": {"doi": "10.1056/NEJMra1706169", "journal": "New England Journal of Medicine", "publication_date": "2018-09-13", "mesh_terms": ["CAR-T Cells", "Immunotherapy", "Leukemia", "Genetic Engineering"]}}
{"_id": "W2100000004", "title": "Tumor microenvironment and resistance to immunotherapy", "text": "The tumor microenvironment (TME) plays a critical role in determining response to cancer immunotherapy. This study investigates how immunosuppressive cells including regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages create barriers to effective anti-tumor immunity. We identify key cytokines and chemokines that shape the TME and propose combination strategies to reprogram the immunosuppressive milieu.", "metadata": {"doi": "10.1016/j.cell.2017.08.004", "journal": "Cell", "publication_date": "2017-09-07", "mesh_terms": ["Tumor Microenvironment", "Immunosuppression", "Regulatory T-Cells"]}}
{"_id": "W2100000005", "title": "PD-1 blockade enhances anti-tumor immunity in melanoma models", "text": "We investigated the efficacy of anti-PD-1 monoclonal antibodies in syngeneic mouse models of melanoma. Treatment with anti-PD-1 antibodies resulted in significant tumor regression in 60% of mice, associated with increased CD8+ T cell infiltration and elevated interferon-gamma production. Combination with anti-CTLA-4 further improved response rates to 85%. These preclinical results support clinical development of PD-1-targeting immunotherapies for melanoma.", "metadata": {"doi": "10.1158/0008-5472.CAN-17-0812", "journal": "Cancer Research", "publication_date": "2016-11-15", "mesh_terms": ["PD-1", "Melanoma", "Mouse Models", "CD8+ T Cells"]}}
{"_id": "W2100000006", "title": "Biomarkers for predicting response to immune checkpoint inhibitors", "text": "Identifying patients likely to respond to immune checkpoint inhibitors remains a major clinical challenge. This comprehensive review examines validated and emerging biomarkers including PD-L1 expression, tumor mutational burden, microsatellite instability, and gene expression signatures. We discuss the strengths and limitations of each biomarker and propose an integrated approach combining multiple factors to improve patient selection.", "metadata": {"doi": "10.1200/JCO.2017.75.4598", "journal": "Journal of Clinical Oncology", "publication_date": "2018-01-20", "mesh_terms": ["Biomarkers", "PD-L1", "Tumor Mutational Burden", "Patient Selection"]}}
{"_id": "W2100000007", "title": "Bispecific antibodies for cancer immunotherapy: design and clinical development", "text": "Bispecific antibodies that simultaneously engage tumor antigens and immune effector cells represent a promising class of cancer immunotherapeutics. This review covers the various bispecific formats including BiTE, DART, and IgG-like molecules. We discuss the CD19xCD3 bispecific blinatumomab as a clinical proof-of-concept and emerging bispecifics targeting solid tumor antigens such as HER2, EGFR, and PSMA.", "metadata": {"doi": "10.1038/nrd.2017.227", "journal": "Nature Reviews Drug Discovery", "publication_date": "2018-02-09", "mesh_terms": ["Bispecific Antibodies", "BiTE", "CD19", "CD3"]}}
{"_id": "W2100000008", "title": "Neoantigens as targets for cancer immunotherapy", "text": "Tumor-specific neoantigens arising from somatic mutations represent ideal targets for personalized cancer immunotherapy. This study describes a computational pipeline for neoantigen prediction from whole-exome sequencing data and validates predicted neoantigens using T cell reactivity assays. We identify neoantigen-specific T cell responses in melanoma patients and demonstrate that neoantigen load correlates with response to checkpoint inhibitors.", "metadata": {"doi": "10.1126/science.aaf1490", "journal": "Science", "publication_date": "2017-03-24", "mesh_terms": ["Neoantigens", "Somatic Mutations", "Personalized Medicine", "Melanoma"]}}
{"_id": "W2100000009", "title": "Small molecule inhibitors of the PD-1/PD-L1 interaction", "text": "While antibodies dominate the immune checkpoint inhibitor landscape, small molecule inhibitors offer potential advantages including oral bioavailability and lower manufacturing costs. This article describes the discovery of peptidomimetic compounds that disrupt the PD-1/PD-L1 protein-protein interaction. Lead compound BMS-1166 showed nanomolar binding affinity and restored T cell function in co-culture assays. Structure-activity relationships and optimization strategies are discussed.", "metadata": {"doi": "10.1021/acs.jmedchem.7b00907", "journal": "Journal of Medicinal Chemistry", "publication_date": "2017-11-09", "mesh_terms": ["Small Molecules", "PD-1", "PD-L1", "Drug Discovery"]}}
{"_id": "W2100000010", "title": "Immune-related adverse events from checkpoint inhibitor therapy", "text": "Immune checkpoint inhibitors can cause immune-related adverse events (irAEs) affecting virtually any organ system. This clinical review provides a comprehensive overview of irAE presentation, grading, and management. We discuss the pathophysiology of common irAEs including colitis, hepatitis, pneumonitis, and endocrinopathies. Evidence-based treatment algorithms using corticosteroids and other immunosuppressants are provided.", "metadata": {"doi": "10.1016/j.annonc.2017.09.023", "journal": "Annals of Oncology", "publication_date": "2017-12-01", "mesh_terms": ["Adverse Events", "Checkpoint Inhibitors", "Colitis", "Autoimmunity"]}}
{"_id": "W2100000011", "title": "Oncolytic viruses as cancer immunotherapy agents", "text": "Oncolytic viruses selectively replicate in and kill cancer cells while sparing normal tissue. Beyond direct oncolysis, these viruses stimulate anti-tumor immunity by releasing tumor antigens and danger signals. This review covers the biology of oncolytic viruses including herpes simplex virus, adenovirus, and vaccinia virus. We discuss talimogene laherparepvec (T-VEC), the first oncolytic virus approved for cancer, and ongoing combination trials.", "metadata": {"doi": "10.1038/nm.4400", "journal": "Nature Medicine", "publication_date": "2017-08-04", "mesh_terms": ["Oncolytic Viruses", "T-VEC", "Herpes Simplex", "Tumor Lysis"]}}
{"_id": "W2100000012", "title": "Cancer vaccines: from tumor antigens to clinical efficacy", "text": "Therapeutic cancer vaccines aim to elicit tumor-specific immune responses by presenting tumor antigens to the immune system. This review traces the evolution of cancer vaccines from early whole-cell preparations to modern approaches using defined antigens, dendritic cell vaccines, and mRNA-based platforms. We analyze factors contributing to the mixed clinical track record and discuss how combination with checkpoint inhibitors may unlock vaccine potential.", "metadata": {"doi": "10.1016/j.immuni.2018.07.009", "journal": "Immunity", "publication_date": "2018-08-21", "mesh_terms": ["Cancer Vaccines", "Dendritic Cells", "mRNA Vaccines", "Tumor Antigens"]}}
{"_id": "W2100000013", "title": "T cell exhaustion in chronic infection and cancer", "text": "T cell exhaustion is a state of dysfunction that arises during chronic antigen exposure. Originally described in chronic viral infections, T cell exhaustion is now recognized as a major barrier to anti-tumor immunity. This study provides a comprehensive transcriptional and epigenetic characterization of exhausted T cells, identifying TOX as a master regulator of exhaustion. Understanding exhaustion mechanisms may enable therapeutic reinvigoration of dysfunctional T cells.", "metadata": {"doi": "10.1038/s41590-018-0144-8", "journal": "Nature Immunology", "publication_date": "2018-07-16", "mesh_terms": ["T Cell Exhaustion", "TOX", "Epigenetics", "Chronic Infection"]}}
{"_id": "W2100000014", "title": "Targeting LAG-3 as a novel immune checkpoint strategy", "text": "Lymphocyte activation gene-3 (LAG-3) is an inhibitory receptor that negatively regulates T cell function. LAG-3 is frequently co-expressed with PD-1 on exhausted T cells, suggesting synergistic inhibitory effects. This article reviews LAG-3 biology and clinical development of LAG-3-targeting antibodies. Early clinical data show promising activity of anti-LAG-3 plus anti-PD-1 combinations in patients who progressed on prior PD-1 therapy.", "metadata": {"doi": "10.1158/2159-8290.CD-18-0367", "journal": "Cancer Discovery", "publication_date": "2018-09-01", "mesh_terms": ["LAG-3", "Immune Checkpoint", "Combination Therapy", "PD-1"]}}
{"_id": "W2100000015", "title": "Adenosine signaling in the tumor microenvironment", "text": "Adenosine accumulates in the hypoxic tumor microenvironment and potently suppresses anti-tumor immunity through A2A receptor signaling on immune cells. This study demonstrates that genetic deletion or pharmacological blockade of A2A receptors enhances tumor control in mouse models. A2A antagonists synergized with PD-1 blockade, providing rationale for combination clinical trials. Small molecule A2A antagonists suitable for clinical development are described.", "metadata": {"doi": "10.1158/0008-5472.CAN-17-2090", "journal": "Cancer Research", "publication_date": "2018-02-15", "mesh_terms": ["Adenosine", "A2A Receptor", "Hypoxia", "Immunosuppression"]}}
{"_id": "W2100000016", "title": "Natural killer cell-based cancer immunotherapy", "text": "Natural killer (NK) cells provide innate immune defense against cancer through recognition of stress ligands and missing self-MHC. This review discusses NK cell biology relevant to cancer immunotherapy, including killer immunoglobulin-like receptor (KIR) genetics and antibody-dependent cellular cytotoxicity. We cover emerging NK cell therapies including adoptive transfer of ex vivo expanded NK cells, CAR-NK cells, and NK cell engagers.", "metadata": {"doi": "10.1016/j.ccell.2017.10.011", "journal": "Cancer Cell", "publication_date": "2017-11-13", "mesh_terms": ["Natural Killer Cells", "KIR", "ADCC", "CAR-NK"]}}
{"_id": "W2100000017", "title": "Tumor-infiltrating lymphocyte therapy for metastatic melanoma", "text": "Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) has achieved durable complete responses in metastatic melanoma patients. This clinical study reports outcomes from 93 patients treated with TIL therapy, showing 24% complete response rate and 56% overall response rate. Responses were associated with persistence of transferred cells and development of memory phenotypes. We discuss manufacturing improvements and strategies to extend TIL therapy to other tumor types.", "metadata": {"doi": "10.1200/JCO.2017.73.6456", "journal": "Journal of Clinical Oncology", "publication_date": "2017-10-10", "mesh_terms": ["TIL Therapy", "Adoptive Cell Transfer", "Melanoma", "Complete Response"]}}
{"_id": "W2100000018", "title": "Antibody-drug conjugates in solid tumors: clinical development update", "text": "Antibody-drug conjugates (ADCs) combine the targeting specificity of monoclonal antibodies with the cytotoxic potency of small molecule drugs. This comprehensive review covers ADC design principles including antibody selection, linker chemistry, and payload classes. We discuss approved ADCs and analyze the clinical development landscape, highlighting promising agents targeting HER2, Trop-2, and Nectin-4 in solid tumors.", "metadata": {"doi": "10.1038/s41571-018-0007-y", "journal": "Nature Reviews Clinical Oncology", "publication_date": "2018-04-24", "mesh_terms": ["Antibody-Drug Conjugates", "HER2", "Trop-2", "Cytotoxic Payloads"]}}
{"_id": "W2100000019", "title": "STING pathway activation in cancer immunotherapy", "text": "The stimulator of interferon genes (STING) pathway senses cytosolic DNA and activates type I interferon responses. STING agonists are being developed as cancer immunotherapy agents to promote dendritic cell activation and T cell priming. This study characterizes novel cyclic dinucleotide STING agonists with improved stability and potency. Intratumoral injection induced complete regression in multiple mouse tumor models.", "metadata": {"doi": "10.1016/j.celrep.2018.05.039", "journal": "Cell Reports", "publication_date": "2018-06-12", "mesh_terms": ["STING", "cGAS", "Type I Interferon", "Cyclic Dinucleotides"]}}
{"_id": "W2100000020", "title": "TIM-3: a promising target for cancer immunotherapy", "text": "T cell immunoglobulin and mucin domain-3 (TIM-3) is an inhibitory receptor expressed on exhausted T cells and other immune populations. TIM-3 and PD-1 co-expression marks terminally exhausted T cells with limited responsiveness to PD-1 blockade alone. This review discusses TIM-3 biology, its ligands including galectin-9 and CEACAM1, and clinical development of TIM-3-targeting antibodies as monotherapy and in combination with PD-1 inhibitors.", "metadata": {"doi": "10.3389/fimmu.2018.01909", "journal": "Frontiers in Immunology", "publication_date": "2018-08-27", "mesh_terms": ["TIM-3", "T Cell Exhaustion", "Galectin-9", "CEACAM1"]}}
{"_id": "W2100000021", "title": "Myeloid-derived suppressor cells in cancer: therapeutic targeting strategies", "text": "Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that accumulate in tumors and suppress anti-tumor immunity. This review covers MDSC biology, including their heterogeneous subtypes (polymorphonuclear and monocytic), immunosuppressive mechanisms, and factors promoting their expansion. We discuss therapeutic strategies to deplete MDSCs or inhibit their function, including chemotherapy, targeted agents, and epigenetic modifiers.", "metadata": {"doi": "10.1016/j.treimm.2017.10.004", "journal": "Trends in Immunology", "publication_date": "2017-12-15", "mesh_terms": ["MDSC", "Immunosuppression", "Myeloid Cells", "Therapeutic Targeting"]}}
{"_id": "W2100000022", "title": "Combination immunotherapy strategies in non-small cell lung cancer", "text": "Non-small cell lung cancer (NSCLC) has become a paradigm for combination immunotherapy development. This clinical review analyzes completed and ongoing trials combining checkpoint inhibitors with chemotherapy, targeted therapy, radiation, and other immunotherapies. We discuss the landmark KEYNOTE-189 trial establishing pembrolizumab plus chemotherapy as first-line standard of care and emerging combinations targeting specific molecular subsets.", "metadata": {"doi": "10.1016/j.jtho.2018.06.007", "journal": "Journal of Thoracic Oncology", "publication_date": "2018-09-01", "mesh_terms": ["NSCLC", "Combination Therapy", "Pembrolizumab", "Chemotherapy"]}}
{"_id": "W2100000023", "title": "Fc receptor engineering for enhanced antibody therapeutics", "text": "The Fc region of therapeutic antibodies mediates effector functions through interaction with Fc receptors. This study describes Fc mutations that enhance binding to activating Fc receptors while reducing binding to inhibitory FcgammaRIIb. Engineered anti-CD20 antibodies showed superior B cell depletion in cynomolgus monkeys compared to wild-type Fc. These Fc engineering approaches may improve efficacy of tumor-targeting antibodies.", "metadata": {"doi": "10.1074/jbc.M117.812842", "journal": "Journal of Biological Chemistry", "publication_date": "2017-11-24", "mesh_terms": ["Fc Receptors", "Antibody Engineering", "CD20", "ADCC"]}}
{"_id": "W2100000024", "title": "Metabolism and cancer immunotherapy: fueling the fight", "text": "Metabolic reprogramming affects both tumor cells and immune cells in the tumor microenvironment. This review explores how metabolic competition between tumors and T cells impacts anti-tumor immunity. We discuss how tumor glucose consumption, lactate production, and amino acid depletion suppress T cell function. Metabolic interventions including dietary modifications and small molecule inhibitors may enhance immunotherapy efficacy.", "metadata": {"doi": "10.1016/j.cmet.2018.07.006", "journal": "Cell Metabolism", "publication_date": "2018-09-04", "mesh_terms": ["Metabolism", "Warburg Effect", "T Cell Function", "Glucose"]}}
{"_id": "W2100000025", "title": "Humanization of mouse monoclonal antibodies for clinical use", "text": "Mouse monoclonal antibodies elicit human anti-mouse antibody (HAMA) responses that limit their therapeutic utility. This methodological article describes CDR grafting and framework optimization approaches for antibody humanization. We present a case study of humanizing an anti-EGFR antibody, demonstrating retention of binding affinity and improved pharmacokinetics. Best practices for humanization including germline gene selection are discussed.", "metadata": {"doi": "10.1016/j.jim.2017.06.008", "journal": "Journal of Immunological Methods", "publication_date": "2017-09-01", "mesh_terms": ["Antibody Humanization", "CDR Grafting", "HAMA", "EGFR"]}}
{"_id": "W2100000026", "title": "Resistance mechanisms to PD-1/PD-L1 blockade therapy", "text": "Despite remarkable responses, many patients fail to respond or develop acquired resistance to PD-1/PD-L1 blockade. This comprehensive analysis identifies primary and acquired resistance mechanisms including loss of tumor antigen presentation (B2M mutations), defects in interferon-gamma signaling (JAK1/2 mutations), and upregulation of alternative checkpoints. Understanding resistance mechanisms is essential for developing rational combination strategies.", "metadata": {"doi": "10.1016/j.ccell.2018.03.017", "journal": "Cancer Cell", "publication_date": "2018-04-09", "mesh_terms": ["Drug Resistance", "PD-1", "B2M", "JAK Mutations"]}}
{"_id": "W2100000027", "title": "Interleukin-15 biology and clinical applications", "text": "Interleukin-15 (IL-15) is a common gamma-chain cytokine essential for NK cell and memory CD8+ T cell development and survival. Unlike IL-2, IL-15 does not expand regulatory T cells, making it an attractive immunotherapy agent. This review covers IL-15 biology, pharmacokinetic properties of different IL-15 formulations (free IL-15, IL-15/IL-15Ra complexes, ALT-803), and clinical trial results in cancer patients.", "metadata": {"doi": "10.1038/nri.2018.47", "journal": "Nature Reviews Immunology", "publication_date": "2018-06-28", "mesh_terms": ["IL-15", "NK Cells", "CD8 T Cells", "Cytokine Therapy"]}}
{"_id": "W2100000028", "title": "Tertiary lymphoid structures in cancer and immunotherapy response", "text": "Tertiary lymphoid structures (TLS) are organized immune aggregates that form at sites of chronic inflammation including tumors. This study demonstrates that TLS presence in tumor specimens predicts response to immune checkpoint inhibitors across multiple tumor types. TLS contain B cells, T cells, and dendritic cells organized similarly to secondary lymphoid organs, suggesting they serve as sites for local immune priming.", "metadata": {"doi": "10.1038/s41586-019-1914-8", "journal": "Nature", "publication_date": "2018-11-12", "mesh_terms": ["Tertiary Lymphoid Structures", "Biomarkers", "B Cells", "Germinal Centers"]}}
{"_id": "W2100000029", "title": "CRISPR-engineered T cells for cancer immunotherapy", "text": "CRISPR-Cas9 gene editing enables precise genetic modification of T cells for cancer immunotherapy. This study reports the first clinical application of CRISPR-edited T cells, in which PD-1 and endogenous TCR were disrupted to enhance activity of NY-ESO-1-specific engineered T cells. Edited T cells were safely infused and persisted in patients with advanced cancer. This demonstrates feasibility of multiplex CRISPR editing for cellular therapy.", "metadata": {"doi": "10.1126/science.aav9051", "journal": "Science", "publication_date": "2018-12-06", "mesh_terms": ["CRISPR-Cas9", "T Cell Engineering", "PD-1 Knockout", "NY-ESO-1"]}}
{"_id": "W2100000030", "title": "Macrophage repolarization strategies in cancer immunotherapy", "text": "Tumor-associated macrophages (TAMs) typically exhibit an immunosuppressive M2-like phenotype that promotes tumor growth and metastasis. This review discusses strategies to reprogram TAMs toward a tumoricidal M1-like phenotype, including CD40 agonists, CSF-1R inhibitors, and PI3Kgamma inhibitors. We analyze clinical data from combination trials of macrophage-targeting agents with checkpoint inhibitors and discuss optimal patient selection strategies.", "metadata": {"doi": "10.1016/j.ccell.2018.05.007", "journal": "Cancer Cell", "publication_date": "2018-06-11", "mesh_terms": ["Macrophages", "TAM", "M1/M2 Polarization", "CD40"]}}
{"_id": "W2100000031", "title": "Antibody effector functions in cancer therapy", "text": "Therapeutic antibodies can eliminate tumor cells through multiple effector mechanisms including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). This comprehensive review discusses the relative contribution of each mechanism for different antibody targets and tumor types. We cover engineering approaches to enhance effector functions and the role of patient FcgammaR polymorphisms in clinical response.", "metadata": {"doi": "10.1016/j.smim.2017.09.002", "journal": "Seminars in Immunology", "publication_date": "2017-12-01", "mesh_terms": ["ADCC", "CDC", "ADCP", "Fc Engineering"]}}
{"_id": "W2100000032", "title": "Epigenetic modifiers enhance cancer immunotherapy", "text": "Epigenetic alterations silence genes involved in antigen presentation and immune recognition, contributing to immune evasion. This study demonstrates that DNA methyltransferase inhibitors and histone deacetylase inhibitors upregulate MHC class I expression and tumor antigen presentation. Combination with PD-1 blockade produced synergistic anti-tumor effects in mouse models, supporting clinical development of epigenetic-immunotherapy combinations.", "metadata": {"doi": "10.1016/j.cell.2018.03.022", "journal": "Cell", "publication_date": "2018-04-05", "mesh_terms": ["Epigenetics", "DNMT Inhibitors", "HDAC Inhibitors", "MHC Class I"]}}
{"_id": "W2100000033", "title": "B7-H3 as an emerging immunotherapy target in solid tumors", "text": "B7-H3 (CD276) is an immune checkpoint molecule overexpressed in many solid tumors with limited expression in normal tissues. This study characterizes B7-H3 expression across tumor types and describes development of a humanized anti-B7-H3 antibody with enhanced effector function. Preclinical studies demonstrate potent anti-tumor activity in neuroblastoma and other B7-H3-expressing tumors, supporting clinical development.", "metadata": {"doi": "10.1158/1078-0432.CCR-17-3062", "journal": "Clinical Cancer Research", "publication_date": "2018-01-15", "mesh_terms": ["B7-H3", "CD276", "Neuroblastoma", "Solid Tumors"]}}
{"_id": "W2100000034", "title": "Neoantigen vaccines for personalized cancer immunotherapy", "text": "Personalized cancer vaccines targeting tumor-specific neoantigens can elicit potent T cell responses. This clinical study reports results from a phase I trial of personalized neoantigen peptide vaccines in melanoma patients. Vaccination induced robust CD4+ and CD8+ T cell responses against predicted neoantigens. Patients with detectable neoantigen-specific T cells prior to vaccination showed reduced recurrence rates.", "metadata": {"doi": "10.1038/nature22991", "journal": "Nature", "publication_date": "2017-07-13", "mesh_terms": ["Neoantigen Vaccines", "Personalized Medicine", "Melanoma", "T Cell Responses"]}}
{"_id": "W2100000035", "title": "OX40 costimulation for cancer immunotherapy", "text": "OX40 (CD134) is a costimulatory receptor expressed on activated T cells. OX40 agonist antibodies promote T cell survival, proliferation, and effector function. This review covers OX40 biology, preclinical studies demonstrating synergy with checkpoint blockade, and clinical development of OX40 agonist antibodies. We discuss optimal sequencing and combination partners for OX40-targeting immunotherapy.", "metadata": {"doi": "10.1158/2326-6066.CIR-17-0547", "journal": "Cancer Immunology Research", "publication_date": "2018-03-01", "mesh_terms": ["OX40", "Costimulation", "T Cell Survival", "Agonist Antibodies"]}}
{"_id": "W2100000036", "title": "Gut microbiome modulates cancer immunotherapy response", "text": "The gut microbiome influences systemic immunity and cancer immunotherapy outcomes. This seminal study demonstrates that specific bacterial species including Akkermansia muciniphila and Faecalibacterium prausnitzii are enriched in patients responding to PD-1 blockade. Fecal microbiota transplantation from responders to germ-free mice enhanced anti-tumor immunity. These findings suggest microbiome modulation as a strategy to improve immunotherapy efficacy.", "metadata": {"doi": "10.1126/science.aan4236", "journal": "Science", "publication_date": "2018-01-05", "mesh_terms": ["Microbiome", "Akkermansia", "PD-1", "Fecal Transplant"]}}
{"_id": "W2100000037", "title": "TIGIT: a key inhibitory checkpoint in tumor immunity", "text": "T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory receptor that competes with the costimulatory receptor CD226 for binding to CD155 and CD112. This study shows TIGIT is highly expressed on tumor-infiltrating T cells and NK cells. TIGIT blockade alone had modest effects but synergized potently with PD-1 blockade in mouse tumor models. Anti-TIGIT antibodies are entering clinical development.", "metadata": {"doi": "10.1016/j.celrep.2017.12.037", "journal": "Cell Reports", "publication_date": "2018-01-09", "mesh_terms": ["TIGIT", "CD155", "CD226", "NK Cells"]}}
{"_id": "W2100000038", "title": "Radiation therapy and immunotherapy combinations: mechanisms and clinical progress", "text": "Radiation therapy can enhance anti-tumor immunity through immunogenic cell death, release of tumor antigens, and modulation of the tumor microenvironment. This review discusses the immunomodulatory effects of radiation and rationale for combining radiation with checkpoint inhibitors. We analyze clinical trials of radiation-immunotherapy combinations and discuss optimal dosing, fractionation, and sequencing to maximize the abscopal effect.", "metadata": {"doi": "10.1016/S1470-2045(18)30383-0", "journal": "Lancet Oncology", "publication_date": "2018-08-01", "mesh_terms": ["Radiation Therapy", "Abscopal Effect", "Immunogenic Cell Death", "Combination Therapy"]}}
{"_id": "W2100000039", "title": "CD47-SIRPalpha checkpoint in cancer macrophage interactions", "text": "CD47 is a 'don't eat me' signal that protects cells from phagocytosis through interaction with SIRPalpha on macrophages. This study demonstrates that CD47 is overexpressed on many tumor types and blocking CD47-SIRPalpha interaction enables macrophage-mediated tumor cell phagocytosis. We describe development of anti-CD47 antibodies and SIRPalpha-Fc fusion proteins and their combination with tumor-targeting antibodies.", "metadata": {"doi": "10.1073/pnas.1710877114", "journal": "PNAS", "publication_date": "2017-10-24", "mesh_terms": ["CD47", "SIRPalpha", "Phagocytosis", "Macrophages"]}}
{"_id": "W2100000040", "title": "Innate immune agonists as cancer immunotherapy adjuvants", "text": "Toll-like receptor (TLR) agonists and other innate immune activators can boost adaptive anti-tumor immunity by activating dendritic cells and promoting type I interferon production. This comprehensive review covers TLR7/8 agonists (imiquimod, resiquimod), TLR9 agonists (CpG oligonucleotides), and RIG-I agonists. We discuss clinical development of innate agonists as monotherapy and in combination with checkpoint inhibitors and cancer vaccines.", "metadata": {"doi": "10.1016/j.immuni.2018.01.004", "journal": "Immunity", "publication_date": "2018-02-20", "mesh_terms": ["TLR Agonists", "Innate Immunity", "CpG", "Dendritic Cells"]}}
{"_id": "W2100000041", "title": "Next-generation sequencing for T cell receptor repertoire analysis in cancer", "text": "T cell receptor (TCR) repertoire analysis provides insights into anti-tumor immune responses. This methodological study describes optimized protocols for TCR-seq including RNA versus DNA templates, primer design, and bioinformatic pipelines. We analyze TCR repertoire diversity in tumor-infiltrating lymphocytes and peripheral blood, demonstrating clonal expansion of tumor-reactive T cells and tracking of neoantigen-specific clonotypes.", "metadata": {"doi": "10.1038/nprot.2017.136", "journal": "Nature Protocols", "publication_date": "2018-01-11", "mesh_terms": ["TCR Sequencing", "Repertoire Analysis", "Clonal Expansion", "NGS"]}}
{"_id": "W2100000042", "title": "IDO1 inhibitors in cancer immunotherapy: promise and challenges", "text": "Indoleamine 2,3-dioxygenase 1 (IDO1) depletes tryptophan and produces immunosuppressive kynurenine metabolites in the tumor microenvironment. Despite promising preclinical data, the IDO1 inhibitor epacadostat failed to improve outcomes when combined with pembrolizumab in a phase III melanoma trial. This analysis examines potential reasons for clinical failure including incomplete pathway inhibition and compensatory mechanisms.", "metadata": {"doi": "10.1158/2159-8290.CD-18-0715", "journal": "Cancer Discovery", "publication_date": "2018-08-01", "mesh_terms": ["IDO1", "Tryptophan", "Kynurenine", "Clinical Trial Failure"]}}
{"_id": "W2100000043", "title": "Regulatory T cell depletion strategies for cancer immunotherapy", "text": "Regulatory T cells (Tregs) suppress anti-tumor immunity and accumulate in the tumor microenvironment. This review discusses strategies to selectively deplete or inhibit Tregs including low-dose cyclophosphamide, anti-CD25 antibodies, and CCR4-targeting agents. We analyze the balance between Treg depletion and autoimmunity risk, discussing approaches to achieve tumor-selective Treg modulation.", "metadata": {"doi": "10.1016/j.ccell.2017.12.007", "journal": "Cancer Cell", "publication_date": "2018-01-08", "mesh_terms": ["Regulatory T Cells", "Treg Depletion", "CD25", "CCR4"]}}
{"_id": "W2100000044", "title": "4-1BB costimulation in cancer immunotherapy", "text": "4-1BB (CD137) is a costimulatory receptor that promotes T cell survival and cytotoxic function. This review covers 4-1BB biology, preclinical anti-tumor activity of 4-1BB agonist antibodies, and clinical development. We discuss the dose-limiting hepatotoxicity observed with some 4-1BB agonists and engineering approaches to develop safer next-generation agents.", "metadata": {"doi": "10.3389/fonc.2018.00135", "journal": "Frontiers in Oncology", "publication_date": "2018-04-26", "mesh_terms": ["4-1BB", "CD137", "Costimulation", "Hepatotoxicity"]}}
{"_id": "W2100000045", "title": "Circulating tumor DNA as a biomarker for immunotherapy response", "text": "Circulating tumor DNA (ctDNA) analysis enables non-invasive monitoring of tumor dynamics. This study evaluates ctDNA as a biomarker for response to immune checkpoint inhibitors. Rapid ctDNA decline after treatment initiation correlated with radiographic response and survival. ctDNA analysis may enable earlier response assessment and identification of pseudoprogression versus true progression.", "metadata": {"doi": "10.1016/j.ccell.2018.01.014", "journal": "Cancer Cell", "publication_date": "2018-02-12", "mesh_terms": ["ctDNA", "Liquid Biopsy", "Response Biomarker", "Pseudoprogression"]}}
{"_id": "W2100000046", "title": "Fc-optimized anti-CD19 antibody for B-cell lymphoma", "text": "We developed an Fc-engineered anti-CD19 antibody with enhanced binding to FcgammaRIIIa to improve ADCC against B-cell malignancies. The optimized antibody showed 10-fold enhanced NK cell-mediated killing compared to wild-type Fc in vitro. In a mouse lymphoma model, the Fc-optimized antibody achieved complete tumor eradication at doses where the wild-type antibody showed minimal activity.", "metadata": {"doi": "10.1182/blood-2017-08-802736", "journal": "Blood", "publication_date": "2018-02-08", "mesh_terms": ["CD19", "Fc Engineering", "ADCC", "B-Cell Lymphoma"]}}
{"_id": "W2100000047", "title": "Synthetic long peptide vaccines in cancer immunotherapy", "text": "Synthetic long peptides (SLP) containing both CD4+ and CD8+ T cell epitopes offer advantages over short peptides for cancer vaccination. This clinical study reports phase II results of an HPV16 E6/E7 SLP vaccine in patients with HPV-positive tumors. Vaccination induced robust T cell responses and produced clinical responses in a subset of patients. Combination with checkpoint inhibitors is being explored.", "metadata": {"doi": "10.1158/1078-0432.CCR-17-1912", "journal": "Clinical Cancer Research", "publication_date": "2018-01-01", "mesh_terms": ["Peptide Vaccines", "HPV", "CD4 T Cells", "CD8 T Cells"]}}
{"_id": "W2100000048", "title": "GITR agonism for cancer immunotherapy", "text": "Glucocorticoid-induced TNFR-related protein (GITR) is a costimulatory receptor that enhances T cell proliferation and function while potentially depleting intratumoral Tregs. This review covers GITR biology, preclinical data supporting GITR agonism for cancer therapy, and clinical development of anti-GITR antibodies. We discuss combination strategies and biomarkers for patient selection.", "metadata": {"doi": "10.1158/2326-6066.CIR-17-0513", "journal": "Cancer Immunology Research", "publication_date": "2018-02-01", "mesh_terms": ["GITR", "Costimulation", "Treg Depletion", "TNFR Superfamily"]}}
{"_id": "W2100000049", "title": "Antibody-based approaches to target solid tumor antigens", "text": "Identifying suitable targets for antibody-based therapy of solid tumors remains challenging. This review analyzes validated and emerging solid tumor targets including HER2, EGFR, Claudin 18.2, Mesothelin, and GPC3. We discuss antibody formats optimized for solid tumors including bispecifics, ADCs, and radioimmunotherapy, and strategies to overcome physical barriers to antibody penetration.", "metadata": {"doi": "10.1016/j.molcel.2018.03.001", "journal": "Molecular Cell", "publication_date": "2018-04-19", "mesh_terms": ["Solid Tumors", "HER2", "EGFR", "Mesothelin"]}}
{"_id": "W2100000050", "title": "Clinical pharmacology of monoclonal antibodies in oncology", "text": "This comprehensive review covers the pharmacokinetics and pharmacodynamics of monoclonal antibodies used in cancer therapy. We discuss factors affecting antibody disposition including target-mediated drug disposition, FcRn recycling, and immunogenicity. Population PK modeling approaches for dose optimization are presented, along with strategies to improve therapeutic index through antibody engineering and dosing regimen optimization.", "metadata": {"doi": "10.1124/pr.117.014456", "journal": "Pharmacological Reviews", "publication_date": "2018-03-01", "mesh_terms": ["Pharmacokinetics", "Monoclonal Antibodies", "TMDD", "FcRn"]}}
